CN102356071A - 作为β-淀粉样肽生产抑制剂的新颖的掺氘α-(N-磺酰氨基)乙酰胺化合物 - Google Patents

作为β-淀粉样肽生产抑制剂的新颖的掺氘α-(N-磺酰氨基)乙酰胺化合物 Download PDF

Info

Publication number
CN102356071A
CN102356071A CN2010800122954A CN201080012295A CN102356071A CN 102356071 A CN102356071 A CN 102356071A CN 2010800122954 A CN2010800122954 A CN 2010800122954A CN 201080012295 A CN201080012295 A CN 201080012295A CN 102356071 A CN102356071 A CN 102356071A
Authority
CN
China
Prior art keywords
compound
fluoro
trifluoro
formula
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800122954A
Other languages
English (en)
Chinese (zh)
Inventor
J.E.小斯塔雷特
K.W.吉尔曼
R.E.奥尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102356071A publication Critical patent/CN102356071A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN2010800122954A 2009-03-19 2010-03-18 作为β-淀粉样肽生产抑制剂的新颖的掺氘α-(N-磺酰氨基)乙酰胺化合物 Pending CN102356071A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16162909P 2009-03-19 2009-03-19
US61/161629 2009-03-19
PCT/US2010/027780 WO2010107984A1 (en) 2009-03-19 2010-03-18 Novel alpha-(n-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production a novel alpha-(n-sulfonamido) acetamide compound incorporating deuterium as inhibitor of beta amyloid peptide production

Publications (1)

Publication Number Publication Date
CN102356071A true CN102356071A (zh) 2012-02-15

Family

ID=42312995

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800122954A Pending CN102356071A (zh) 2009-03-19 2010-03-18 作为β-淀粉样肽生产抑制剂的新颖的掺氘α-(N-磺酰氨基)乙酰胺化合物

Country Status (7)

Country Link
US (1) US8044077B2 (cg-RX-API-DMAC7.html)
EP (1) EP2408757B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012520896A (cg-RX-API-DMAC7.html)
CN (1) CN102356071A (cg-RX-API-DMAC7.html)
AR (1) AR075903A1 (cg-RX-API-DMAC7.html)
TW (1) TW201038266A (cg-RX-API-DMAC7.html)
WO (1) WO2010107984A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1465861T3 (da) 2001-12-20 2009-08-31 Bristol Myers Squibb Co Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1617852A (zh) * 2001-12-20 2005-05-18 布里斯托尔-迈尔斯斯奎布公司 α-(N-磺酰氨基)乙酰胺衍生物作为β-淀粉样蛋白抑制剂
WO2009058552A1 (en) * 2007-10-31 2009-05-07 Bristol-Myers Squibb Company A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
SK282833B6 (sk) * 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
BR9710752A (pt) 1996-07-22 1999-08-17 Monsanto Co Inbidores de metaloprotease de sulfonamida de tiol
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するTNF―α産生抑制剤
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
ATE280152T1 (de) 1999-01-27 2004-11-15 Wyeth Corp Acetylenische sulfonamid-thiol-tace-inhibitoren
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2004230844B2 (en) * 2003-03-31 2010-12-09 Wyeth Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
EP1680406A1 (en) 2003-10-29 2006-07-19 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
RU2378258C2 (ru) 2004-07-13 2010-01-10 Ф. Хоффманн-Ля Рош Аг Производные сульфонамида
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
CA2641013A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
RU2008131051A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US20110059940A1 (en) 2008-05-08 2011-03-10 Bristol- Myers Squibb Company 2-Aryl Glycinamide Derivatives
JP2012520875A (ja) * 2009-03-19 2012-09-10 ブリストル−マイヤーズ スクイブ カンパニー ベータアミロイドペプチド産生阻害剤としての新規アルファ−(n−スルホンアミド)アセトアミド化合物
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1617852A (zh) * 2001-12-20 2005-05-18 布里斯托尔-迈尔斯斯奎布公司 α-(N-磺酰氨基)乙酰胺衍生物作为β-淀粉样蛋白抑制剂
WO2009058552A1 (en) * 2007-10-31 2009-05-07 Bristol-Myers Squibb Company A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Also Published As

Publication number Publication date
TW201038266A (en) 2010-11-01
US8044077B2 (en) 2011-10-25
EP2408757B1 (en) 2014-06-25
WO2010107984A1 (en) 2010-09-23
AR075903A1 (es) 2011-05-04
EP2408757A1 (en) 2012-01-25
JP2012520896A (ja) 2012-09-10
US20100240719A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
KR20230004501A (ko) 안지오텐신 ⅱ와 관련된 질병, 장애, 또는 병태의 치료 및/또는 예방에 유용한 신규 화합물
AU2015220873A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease
EA019001B1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EP2295417A1 (en) Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound
JP2019514922A (ja) N−{6−(2−ヒドロキシプロパン−2−イル)−2−[2−(メチルスルホニル)エチル]−2h−インダゾール−5−イル}−6−(トリフルオロメチル)ピリジン−2−カルボキサミドの多形体
WO2018208855A1 (en) Sphingosine 1 phosphate receptor agonists for neuroprotection
US7977362B2 (en) Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
TWI582080B (zh) 礦皮質素受體拮抗劑
EP2408757B1 (en) A novel alpha-(n-sulfonamido) acetamide compound incorporating deuterium as inhibitor of beta amyloid peptide production
JP2012520899A (ja) アルツハイマー病の処置のためのチオフェニルスルホンアミド
TW202115017A (zh) 小分子menin抑制劑
CN101553484A (zh) 以喜巴辛的被改质三环单位为基础的凝血酶受体拮抗剂
EP2408450B1 (en) Alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US11013728B2 (en) Cyclin-dependent kinase 8 and/or 19 inhibitor
WO2016006593A1 (ja) 新規ベンズオキサジン誘導体及びこれを含有する医薬
JP7035275B2 (ja) ベンズイミダゾール化合物、及びアルツハイマー病又はハンチントン病の治療のためのその使用
CN114828958A (zh) 含环烷基的羧酸和其用途
TW202024083A (zh) 3,9-二氮雜螺[5.5]十一烷化合物
JP2021525792A6 (ja) ベンズイミダゾール化合物、及びアルツハイマー病又はハンチントン病の治療のためのその使用
JP2012508743A (ja) アゼピノン誘導体
CN120271571A (zh) 一类谷胺酰胺环化酶抑制剂及其用途
EA050344B1 (ru) Кристаллическое соединение антагонистов ацетилхолиновых мускариновых рецепторов м1
WO2019022234A1 (ja) 炎症性腸疾患の治療剤又は予防剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120215